NCT06783153View on ClinicalTrials.gov

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Radiotherapy Induced DiarrheaAcute Radiation EnteritisProstate CancerCervical AdenocarcinomaBladder (Urothelial, Transitional Cell) CancerRectal AdenocarcinomaPelvic RadiotherapyRifaximin
Interventions
DRUG

Rifaximin 550 MG

Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.

DRUG

Standard Care Chemoradiation

Patients will receive standard chemotherapy and/or radiation

Trial Locations (1)

35516

Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER